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Abstract
Resolvins are a group of molecules derived from omega-3 fatty acids. They are part of a biochemical
program that allows inflamed tissues to return to homeostasis once the need for the inflammatory
response is over. Resolvins act in very low dose ranges in vitro and in vivo. New data suggest that they
might have the potential to become very potent analgesic drugs in inflammatory pain.
Introduction
Chronic inflammation is a feature of a large number of
painful chronic degenerative diseases, such as arthritis,
low back pain, and inflammatory bowel disease, among
many others. These conditions cause pain and suffering to
millions, not to mention the high healthcare and socio-
economic costs involved in managing these conditions.
Patients with chronic inflammation are currently pre-
scribed cyclooxygenase (COX) inhibitors or opioids to
control their pain; however, long-term use of these drugs
leads to significant side effects, and the analgesic effect is
even lower in chronic pain than in acute pain. Unselective
COX inhibitors may cause gastrointestinal bleeding and
kidney damage, and selective COX2 inhibitors may
increase the risk of cardiovascular disease. Long-term use
of opioids leads to tolerance and the need to increase
doses,andcausesunwantedsideeffectssuchasdrowsiness,
constipation,nausea,sedation,andcognitivedisturbances.
Thus, an alternative, powerful, and well-tolerated treat-
ment of chronic inflammatory pain would be of great
interest to both patients and doctors.
Physiologically, acute inflammation is an important
process for successful host defense, and should cease
once the stimulus is removed. The process by which
inflammation is terminated is not only passive; for
example, by elimination of the antigen, it is now
understood to be an active process [1]. Important
molecular players involved in the active termination of
inflammation are the “specialized pro-resolving media-
tors” [2], which include the essential fatty acid-derived
lipoxins, resolvins, protectins, and maresins [1]. If this
active process fails, chronic inflammation may ensue. Not
only does chronic inflammation underlie disorders like
rheumatism, inflammatory bowel disease, and other
autoimmune diseases, it has also been implicated in the
pathogenesis of diverse neurological disorders like Par-
kinson’s and Alzheimer’s disease, cancer, chronic heart
failure, and pain. A closer look at the specialized pro-
resolving mediators described above that help resolve
inflammation may help us find a more effective treatment
to combat inflammatory pain.
Lipoxins—as all specialized pro-resolving mediators do—
stimulate the uptake of apoptotic polymorphnuclear
leukocytes and activate antimicrobial defense mechan-
isms. This action is supported by these mediators shifting
to an anti-inflammatory response; lipoxins inhibit the
production and action of chemokines and inflammatory
cytokines while stimulating anti-inflammatory cytokines
[3]. Resolvins block the production of proinflammatory
mediators and regulate leukocyte trafficking to inflamma-
tory sites as well as clearance of neutrophils from mucosal
surfaces. Specifically, resolvins limit polymorphnuclear
leukocyte migration and infiltration across the endothe-
lium. Protectins additionally possess protective actions in
neural tissues and systems. Like resolvins, protectins stop
polymorphnuclear leukocyte infiltration and they also
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Macrophages, which are also essential in inflammation,
biosynthesizethefourthspecializedpro-resolvingmediator
on our list, maresins (macrophage mediator in resolving
inflammation), from docosahexaenoic acid (DHA),
thereby contributing to the anti-inflammatory action of
DHA. Maresins also contribute to wound healing and
host defense. In summary, each of these specialized pro-
resolving mediators is temporally and spatially biosynthe-
sizedtoactivelyregulateinflammationresolutionbyacting
on specific receptors initiating anti-inflammatory and pro-
resolving signals to terminate inflammation and prevent
chronic disease [4] (Figure 1). Among these specialized
pro-resolving mediators, the resolvins in particular have
recently received attention by researchers and been studied
in various disease models, including pain.
The Serhan laboratory at Brigham and Women’s
Hospital at Harvard Medical School discovered resolvins
when they were looking for potential endogenous
bioactive compounds derived from omega-3 fatty acids
[2,5]. Omega-3 fatty acids such as eicosapentaenoic
acid (EPA) and DHA have long been known to have
beneficial effects in several diseases, including
atherosclerosis, asthma, cardiovascular disorders, and
cancer [6]. The American Heart Association even
recommends the intake of fish rich in omega-3 fatty
acids for cardiovascular disease prevention. However, it
was not known exactly how omega-3 fatty acids worked
in the diverse clinical trials. Furthermore, in some of the
trials, omega-3 fatty acids had been given together with
aspirin, which is anti-inflammatory in its own right. The
Serhan laboratory therefore set out to analyze the
interaction of EPA and DHA with aspirin and to identify
molecular components derived from the fatty acids.
The Serhangroup usedlipidomic analysesin the model of
the mouse air pouch (a subcutaneous pouch induced by
injection of air that is frequently used to study inflamma-
tion) and described previously unknown biosynthetic
circuits leading from omega-3 fatty acids to the novel
17R-hydroxy series of docosanoids [2,5] (Figure 2). They
found, in particular, that treatment with aspirin enhanced
the production of these compounds. These specialized
pro-resolving mediators, when administered in animal
models of inflammation such as peritonitis, colitis, or
asthma, accelerated the return to homeostasis (for review
see [5]). Interestingly, one of the early applications of
resolvins to be investigated was in periodontitis [7], and
Figure 1. Resolution of inflammation
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Schematic representation showing the processes leading to the resolution of inflammation (blue). If this resolution fails, chronic inflammation, scarring, and loss of
function may ensue. PGD2, prostaglandin D2; PGE2, prostaglandin E2; SPM, specialized pro-resolving mediator. Modified from [4].
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clinical trial has been completed [9].
Given that the resolvins are derived from omega-3 fatty
acids (i.e., from essential nutritional factors) and that
they are endogenous anti-inflammatory substances, it
seemed a likely hypothesis that they would also have an
effect on inflammatory-related pain. In 2010, Xu and
colleagues explored this question in an extensive study
published in Nature Medicine [10] and based on their
results they proposed that resolvins could be developed
to become potent analgesics. Further models and details
of mechanisms of action have become known since then
and will be summarized below. Given the increasing
awareness of the important role of low-grade chronic
inflammation in chronic human pain disorders, the
impact of resolvins may go far beyond just a classifica-
tion as a compound that acts against acute inflammation
and inflammatory pain; they might also be developed
into potent analgesics that could be used to treat
different types of chronic pain.
Analgesic actions of resolvins
Xu and colleagues performed a comprehensive study to
explore the effects of resolvins in animal models of pain
[10]. They tested two different resolvin molecules, RvD1
and RvE1, for their ability to reduce inflammatory
pain behavior in mice, and found both molecules to be
effective. They reduced pain induced by inflammation
caused by intraplantar injection of formalin, Freund’s
complete adjuvant (CFA), and carrageenan. Interestingly,
in the formalin model, only the second phase of pain
behavior (which is likely mediated by spinal cord
mechanisms) was attenuated, indicating a central action
of the molecules via the chemerin receptor 23 (ChemR23;
also known as chemokine receptor-like 1), which is a G
protein-coupled receptor for resolvin, present on noci-
ceptive neurons in the dorsal horn of the spinal cord.
Figure 2. Biochemistry of resolvins
Poly-unsaturated fatty acids (PUFA)
eicosapentaenoic acid
docosahexaenoic acid
Eicosapentanoic acid (EPA) is converted to resolvin E1 (RvE1) via several steps. The first step requires either aspirin and cyclooxygenase 2 (COX-2) or P450-
like enzymes in microbes. In the second step, RvE1 is synthesized from its precursor through a lipoxygenase (LOX)-like mechanism involving leukocytes.
Docosahexaenoic acid (DHA) gives rise to the resolvin D series (RvDs) and to protectin D1 (PD1). Again, several intermediate steps are required involving
polymorphonuclear leukocytes and aspirin. Adapted from [28] © copyright 2006, with permission from Elsevier.
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vanilloid1 (TRPV1), also known as the capsaicinreceptor.
In the carrageenan model, peripheral actions were also
found; specifically, a reduction in local inflammation
shown by reduced edema, reduced leukocyte infiltration,
and reduced production of proinflammatory cytokines.
Intriguingly, RvE1 did not alter responses to painful
stimuli in mice that had not undergone inflammation or
injury. This means that resolvins affected only pathologi-
cal pain sensations, not normal sensations evoked by
painful stimuli. RvE1 was also effective in reducing pain
behavior after direct injection of the irritant capsaicin and
the proinflammatory cytokine tumor necrosis factor-
alpha (TNF) into the tissue. Also, RvE1 reduced pain
behavior in a model of tissue injury and in a model of
neuropathic pain (spinal nerve ligation).
To electrophysiologically characterize the mechanism of
action of RvE1, Xu and colleagues used patch-clamp
recording to record spontaneous excitatory postsynaptic
currents (sEPSCs) in lamina II neurons ex vivo in isolated
spinal cord slices from mice. RvE1 did not alter basal
synaptic transmission but blocked the TNF-induced
increase in sEPSC frequency. Subsequently, the authors
showed that RvE1 inhibited glutamate release by a
pathway dependent on the extracellular signal-regulated
kinase (ERK). ERK belongs to the mitogen-activated
protein kinases (MAPKs), which play critical roles in
regulating neural plasticity and inflammatory responses
(Figure 3). The ERK pathway is activated in spinal cord
dorsal horn neurons by nociceptive activity and plays a
critical role in central sensitization [11]. Blocking the
ERK pathway is therefore considered a promising
therapeutic target for the treatment of pain [12].
In a further series of experiments, Xu et al. [10] also
showed that RvE1 reduced the potentiation of N-methyl-
D-aspartic acid (NMDA) glutamate receptor currents by
TNF, again via an ERK-mediated pathway. Hyperactivity
of spinal NMDA receptors is a well-known mechanism of
mechanical allodynia (i.e., hypersensitivity to innocuous
mechanical stimuli). After application of RvE1, the
NMDA glutamate receptor currents were back to normal,
thus the spinal synaptic plasticity implicated in pain
hypersensitivity was reverted.
In summary, the resolvins, at very low doses, effectively
reduced inflammatory pain symptoms in different
mouse models, through both peripheral and central
actions, without altering basal pain sensitivity.
Since the publication of the first paper by Xu et al.
describing the analgesic effect of resolvins [10], others
have followed. These new studies described positive
effects in other pain models, and have uncovered
additional mechanisms. RvD1 was shown to prevent
and to transiently attenuate postoperative pain in a rat
model [13]. In this study, tactile allodynia and hyper-
algesia, measured 2 weeks after a skin and muscle
incision/retraction procedure, was prevented by 40 ng
of intrathecal RvD1 given 2 days after the operation.
If RvD1 was given on postoperative day 9 or 17, the effect
was only transient and incomplete. In a model of
adjuvant-induced arthritis in rats, RvD1 had antihyper-
algesic effects, which were partially related to decreased
TNF and interleukin-1b in the rat hind paw [14]. In this
model, systemic administration of the resolvins was
effective. Supporting the inhibiting action of resolvins on
TRP channels, which are of paramount importance in
nociception, RvD1 inhibited further members of this
receptor family in cell cultures, namely TRPA1, TRPV3,
and TRPV4 [15]. Subsequent in vivo experiments then
demonstrated that when agonists of these receptors were
injected into mouse hind paws, pain behavior was
induced, which could be attenuated when the mice were
pretreated with local intradermal injection of RvD1.
Discussion
Pain caused by chronic inflammation, as in arthritis,
inflammatory bowel disease, low back pain, and neuro-
pathic pain, causes suffering and high healthcare and
socioeconomic costs. Long-term use of the analgesics
available today is limited by side effects so there is the
need for new, effective, and well-tolerated analgesics.
Figure 3. Assumed mode of action of RvE1 in inflammatory pain
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According to the findings of Xu et al. [10], resolvin E1 (RvE1) reduces
thermal hyperalgesia through a TRPV1-, TNFa-, and pERK-dependent
mechanism, while mechanical allodynia is reduced via a TNFa-, glutamate-,
pERK-, and NMDA-R-dependent pathway.
NMDA-R, N-methyl-D-aspartic acid receptor; pERK, phosphorylated
extracellular signal-regulated kinase; TNFa, tumor necrosis factor-alpha;
TRPV1, transient receptor potential vanilloid 1. Modified from [10].
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the resolvins may be ideal candidates for such novel
analgesics. As they are lipid molecules normally pro-
duced in the body, resolvins counteract inflammation in
a physiological way. Their precursors, the omega-3 fatty
acids, have been tested with some success in pain
conditions [16], although a recent meta-analysis could
not show a definitive effect [17]. However, resolvins
appear to work at concentrations about 10,000 times
lower than that needed for omega-3 fatty acids, which is
advantageous for drug development.
Intriguingly, one of the mechanisms that Xu et al. [10]
identified for the analgesic action of the resolvins is that
they block various TRP receptors (particularly the TRPV1
receptor), which are mainly expressed on nociceptive
neurons and are thus potential targets for very specific
analgesic drugs, such as the TRPV1 antagonists. However,
the use of those drugs has lead to serious side effects, such
as high fever caused by the blocking of thermal afferents.
Since resolvins counteract the function of the TRPV1
receptor by blocking TRPV1-dependent release of the
excitatory neurotransmitter glutamate rather than by
direct antagonism, their mode of action might avoid
such life-threatening side effects. Side effects might be
even more reduced with the use of TRP receptor-specific
resolvins,asrecentlydemonstrated invitroand invivo [18].
This receptor specificity may potentially pave the way to a
more specific, tailored treatment for individual pain
symptoms such as thermal or mechanical hyperalgesia.
A further potential advantage of resolvins is that they
may have a dual function as both an analgesic and an
inflammatory disease-modifying drug. In fact, a number
of molecules with this potential have already been
investigated, including: nerve growth factor and its
antagonists in the treatment of nerve lesions, neuropathic
pain, or osteoarthritis; erythropoietin in diabetic neuro-
pathy; and cytokine inhibitors in rheumatoid arthritis
[19]. Unfortunately,ofthese, currently onlythe latterhave
made it to clinical application and other molecules have
failed or are still at an early experimental stage [20,21].
Given the potent anti-inflammatory effects of the
resolvins, individuals with pain conditions in which
chronic inflammation is the key factor of pathophysiology
might be the best candidates to test the resolvins in the
clinic. For example, acute complex regional pain syn-
dromes, which are characterized by localized exaggerated
post-traumatic inflammation and peripheral and central
nociceptive sensitization [22], might be good candidate
diseases to be treated by resolvins.
The challenge now, as it is for every promising molecule
at the preclinical stage of investigation, will be to develop
resolvins into a clinically applicable form. Many of the
experimental applications have been via the intrathecal
route (i.e., into the cerebrospinal fluid), which would
very much limit the application in humans. As a drug,
these molecules would need to be stable, so that they
could be taken orally, for example, and be long-acting.
Because they act on the immune system, they might have
unexpected unwanted side effects, which will need to be
investigated. Furthermore, although the results by Xu
et al. [10] and other research groups are impressive and
reasonable, the size of the effect on pain behavior in the
animals is moderate. Other analgesic drugs, which had
even stronger effects than the resolvins in animalmodels,
have failed in clinical human trials because their impact
was not sufficiently different that of a placebo [23,24].
The reason might be that human pain still significantly
differs even from the best and most elaborated animal
pain models. With all these caveats, using the resolvins
in clinical trials will be a very elegant way to test the
hypothesis of chronic low-grade inflammation as a
pathogenic factor, not only in chronic pain [25], but
also in many other disorders, with the view to reducing
morbidity and mortality in today’s societies [26,27]
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